The Importance of Inflammatory and Angiogenic Markers in the Evaluation of Early Cardiovascular Disease Risk in Women with Hypertensive Disorders of Pregnancy
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. TNF-α
3.2. IL-6
3.3. Angiogenic Factors
3.4. Traditional Cardiovascular Risk Factors
3.5. Arterial Aging Signs and Angiogenic Factors
3.6. Angiogenic Factors and Echocardiogram Measurements
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Khedagi, A.M.; Bello, N.A. Hypertensive Disorders of Pregnancy. Cardiol. Clin. 2021, 39, 77–90. [Google Scholar] [CrossRef] [PubMed]
- Hutcheon, J.A.; Lisonkova, S.; Joseph, K.S. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best. Pract. Res. Clin. Obs. Gynaecol. 2011, 25, 391–403. [Google Scholar] [CrossRef] [PubMed]
- Rana, S.; Lemoine, E.; Granger, J.P.; Karumanchi, S.A. Preeclampsia: Pathophysiology, Challenges, and Perspectives. Circ. Res. 2019, 124, 1094–1112. [Google Scholar] [CrossRef] [PubMed]
- Steegers, E.A.P.; von Dadelszen, P.; Duvekot, J.J.; Pijnenborg, R. Pre-Eclampsia. Lancet 2010, 376, 631–644. [Google Scholar] [CrossRef] [PubMed]
- Coutinho, T.; Lamai, O.; Nerenberg, K. Hypertensive Disorders of Pregnancy and Cardiovascular Diseases: Current Knowledge and Future Directions. Curr. Treat. Options Cardiovasc. Med. 2018, 20, 56. [Google Scholar] [CrossRef] [PubMed]
- Wu, P.; Haththotuwa, R.; Kwok, C.S.; Babu, A.; Kotronias, R.A.; Rushton, C.; Zaman, A.; Fryer, A.A.; Kadam, U.; Chew-Graham, C.A.; et al. Preeclampsia and Future Cardiovascular Health. Circ. Cardiovasc. Qual. Outcomes 2017, 10, e003497. [Google Scholar] [CrossRef]
- Dall’Asta, A.; D’Antonio, F.; Saccone, G.; Buca, D.; Mastantuoni, E.; Liberati, M.; Flacco, M.E.; Frusca, T.; Ghi, T. Cardiovascular events following pregnancy complicated by pre-eclampsia with emphasis on comparison between early- and late-onset forms: Systematic review and meta-analysis. Ultrasound Obstet. Gynecol. 2021, 57, 698–709. [Google Scholar] [CrossRef]
- Riise, H.K.R.; Sulo, G.; Tell, G.S.; Igland, J.; Nygård, O.; Iversen, A.C.; Daltveit, A.K. Association Between Gestational Hypertension and Risk of Cardiovascular Disease Among 617 589 Norwegian Women. J. Am. Heart Assoc. 2018, 7, e008337. [Google Scholar] [CrossRef]
- Brouwers, L.; van der Meiden-van Roest, A.J.; Savelkoul, C.; Vogelvang, T.E.; Lely, A.T.; Franx, A.; van Rijn, B.B. Recurrence of pre-eclampsia and the risk of future hypertension and cardiovascular disease: A systematic review and meta-analysis. BJOG 2018, 125, 1642–1654. [Google Scholar] [CrossRef]
- Parikh, N.I.; Laria, B.; Nah, G.; Singhal, M.; Vittinghoff, E.; Vieten, C.; Stotland, N.; Coleman-Phox, K.; Adler, N.; Albert, M.A.; et al. Cardiovascular Disease-Related Pregnancy Complications Are Associated with Increased Maternal Levels and Trajectories of Cardiovascular Disease Biomarkers During and After Pregnancy. J. Womens Health 2020, 29, 1283–1291. [Google Scholar] [CrossRef]
- Ehrenthal, D.B.; Rogers, S.; Goldstein, N.D.; Edwards, D.G.; Weintraub, W.S. Cardiovascular Risk Factors One Year after a Hypertensive Disorder of Pregnancy. J. Womens Health 2015, 24, 23–29. [Google Scholar] [CrossRef]
- Östlund, E.; Al-Nashi, M.; Hamad, R.R.; Larsson, A.; Eriksson, M.; Bremme, K.; Kahan, T. Normalized endothelial function but sustained cardiovascular risk profile 11 years following a pregnancy complicated by preeclampsia. Hypertens. Res. 2013, 36, 1081–1087. [Google Scholar] [CrossRef] [PubMed]
- Escouto, D.C.; Green, A.; Kurlak, L.; Walker, K.; Loughna, P.; Chappell, L.; Pipkin, F.B.; Bramham, K. Postpartum evaluation of cardiovascular disease risk for women with pregnancies complicated by hypertension. Pregnancy Hypertens. 2018, 13, 218–224. [Google Scholar] [CrossRef] [PubMed]
- Benschop, L.; Duvekot, J.J.; Roeters van Lennep, J.E. Future risk of cardiovascular disease risk factors and events in women after a hypertensive disorder of pregnancy. Heart 2019, 105, 1273–1278. [Google Scholar] [CrossRef]
- Umesawa, M.; Kobashi, G. Epidemiology of hypertensive disorders in pregnancy: Prevalence, risk factors, predictors and prognosis. Hypertens. Res. 2017, 40, 213–220. [Google Scholar] [CrossRef]
- Hong, K.; Kim, S.H.; Cha, D.; Park, H. Defective Uteroplacental Vascular Remodeling in Preeclampsia: Key Molecular Factors Leading to Long Term Cardiovascular Disease. Int. J. Mol. Sci. 2021, 22, 11202. [Google Scholar] [CrossRef]
- Harmon, A.C.; Cornelius, D.C.; Amaral, L.M.; Faulkner, J.L.; Cunningham, M.W., Jr.; Wallace, K.; LaMarca, B. The role of inflammation in the pathology of preeclampsia. Clin. Sci. 2016, 130, 409–419. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Shi, D.; Chen, L. Lipid profile and cytokines in hypertension of pregnancy: A comparison of preeclampsia therapies. J. Clin. Hypertens. 2018, 20, 394–399. [Google Scholar] [CrossRef]
- Redman, C.W.G.; Staff, A.C. Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am. J. Obstet. Gynecol. 2015, 213, S9.e1–S9.e4. [Google Scholar] [CrossRef]
- Perni, U.; Sison, C.; Sharma, V.; Helseth, G.; Hawfield, A.; Suthanthiran, M.; August, P. Angiogenic Factors in Superimposed Preeclampsia. Hypertension 2012, 59, 740–746. [Google Scholar] [CrossRef]
- Levine, L.; Arany, Z.; Kern-Goldberger, A.; Koelper, N.; Lewey, J.; Sammel, M.D.; Elovitz, M.A.; Ky, B. Soluble Flt1 levels are associated with cardiac dysfunction in Black women with and without severe preeclampsia. Hypertens. Pregnancy 2021, 40, 44–49. [Google Scholar] [CrossRef] [PubMed]
- Vitoratos, N.; Economou, E.; Iavazzo, C.; Panoulis, K.; Creatsas, G. Maternal Serum Levels of TNF-Alpha and IL-6 Long after Delivery in Preeclamptic and Normotensive Pregnant Women. Mediators Inflamm. 2010, 2010, 908649. [Google Scholar] [CrossRef] [PubMed]
- Noori, M.; Donald, A.E.; Angelakopoulou, A.; Hingorani, A.D.; Williams, D.J. Prospective Study of Placental Angiogenic Factors and Maternal Vascular Function Before and After Preeclampsia and Gestational Hypertension. Circulation 2010, 122, 478–487. [Google Scholar] [CrossRef] [PubMed]
- Akhter, T.; Wikström, A.K.; Larsson, M.; Larsson, A.; Wikström, G.; Naessen, T. Association between angiogenic factors and signs of arterial aging in women with pre-eclampsia. Ultrasound Obs. Gynecol. 2017, 50, 93–99. [Google Scholar] [CrossRef] [PubMed]
- Kvehaugen, A.S.; Dechend, R.; Ramstad, H.B.; Troisi, R.; Fugelseth, D.; Staff, A.C. Endothelial function and circulating biomarkers are disturbed in women and children after preeclampsia. Hypertension 2011, 58, 63–69. [Google Scholar] [CrossRef] [PubMed]
- Bokslag, A.; Franssen, C.; Alma, L.J.; Kovacevic, I.; van Kesteren, F.; van Teunissen, P.W.; Kamp, O.; Ganzevoort, W.; Hordijk, P.L.; de Groot, M.; et al. Early-onset preeclampsia predisposes to preclinical diastolic left ventricular dysfunction in the fifth decade of life: An observational study. PLoS ONE 2018, 13, e0198908. [Google Scholar] [CrossRef]
- Gaugler-Senden, I.P.M.; Tamsma, J.T.; van der Bent, C.; Kusters, R.; Steegers, E.A.P.; de Groot, C.J.M. Angiogenic factors in women ten years after severe very early onset preeclampsia. PLoS ONE. 2012, 7, e43637. [Google Scholar] [CrossRef]
- Garrido-Gimenez, C.; Mendoza, M.; Cruz-Lemini, M.; Galian-Gay, L.; Sanchez-Garcia, O.; Granato, C.; Rodriguez-Sureda, V.; Rodriguez-Palomares, J.; Carreras-Moratonas, E.; Cabero-Roura, L.; et al. Angiogenic Factors and Long-Term Cardiovascular Risk in Women That Developed Preeclampsia During Pregnancy. Hypertension 2020, 76, 1808–1816. [Google Scholar] [CrossRef]
- Tanz, L.J.; Stuart, J.J.; Missmer, S.A.; Rimm, E.B.; Sumner, J.A.; Vadnais, M.A.; Rich-Edwards, J.W. Cardiovascular biomarkers in the years following pregnancies complicated by hypertensive disorders or delivered preterm. Pregnancy Hypertens. 2018, 13, 14–21. [Google Scholar] [CrossRef]
- Freeman, D.J.; McManus, F.; Brown, E.A.; Cherry, L.; Norrie, J.; Ramsay, J.E.; Clark, P.; Walker, I.D.; Sattar, N.; Greer, I.A. Short- and Long-Term Changes in Plasma Inflammatory Markers Associated With Preeclampsia. Hypertension 2004, 44, 708–714. [Google Scholar] [CrossRef]
- Black, K.D.; Horowitz, J.A. Inflammatory Markers and Preeclampsia: A Systematic Review. Nurs. Res. 2018, 67, 242–251. [Google Scholar] [CrossRef]
- Alijotas-Reig, J.; Esteve-Valverde, E.; Ferrer-Oliveras, R.; Llurba, E.; Gris, J.M. Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review. Clin. Rev. Allerg. Immunol. 2017, 53, 40–53. [Google Scholar] [CrossRef] [PubMed]
- Tousoulis, D.; Oikonomou, E.; Economou, E.K.; Crea, F.; Kaski, J.C. Inflammatory cytokines in atherosclerosis: Current therapeutic approaches. Eur. Heart J. 2016, 37, 1723–1732. [Google Scholar] [CrossRef] [PubMed]
- Alijotas-Reig, J.; Llurba, E.; Gris, J.M. Potentiating maternal immune tolerance in pregnancy: A new challenging role for regulatory T cells. Placenta 2014, 35, 241–248. [Google Scholar] [CrossRef]
- Majetschak, M.; Obertacke, U.; Schade, F.U.; Bardenheuer, M.; Voggenreiter, G.; Bloemeke, B.; Michael, H. Tumor necrosis factor gene polymorphisms, leukocyte function, and sepsis susceptibility in blunt trauma patients. Clin. Diagn. Lab. Immunol. 2002, 9, 1205–1211. [Google Scholar] [CrossRef] [PubMed]
- Wedekind, L.; Belkacemi, L. Altered cytokine network in gestational diabetes mellitus affects maternal insulin and placental-fetal development. J. Diabetes Complicat. 2016, 30, 1393–1400. [Google Scholar] [CrossRef]
- Quenby, S.; Bates, M.; Doig, T.; Brewster, J.; Lewis-Jones, D.I.; Johnson, P.M.; Vince, G. Pre-implantation endometrial leukocytes in women with recurrent miscarriage. Hum. Reprod. 1999, 14, 2386–2391. [Google Scholar] [CrossRef]
- Leibowitz, A.; Schiffrin, E.L. Immune mechanisms in hypertension. Curr. Hypertens. Rep. 2011, 13, 465–472. [Google Scholar] [CrossRef]
- Chen, L.M.; Liu, B.; Zhao, H.B.; Stone, P.; Chen, Q.; Chamley, L. IL-6, TNFα and TGFβ Promote Nonapoptotic Trophoblast Deportation and Subsequently Causes Endothelial Cell Activation. Placenta 2010, 31, 75–80. [Google Scholar] [CrossRef]
- Mohseni, Z.; Derksen, E.; Oben, J.; Al-Nasiry, S.; Spaanderman, M.E.A.; Ghossein-Doha, C. Cardiac dysfunction after preeclampsia; an overview of pro- and anti-fibrotic circulating effector molecules. Pregnancy Hypertens. 2021, 23, 140–154. [Google Scholar] [CrossRef]
- Fontes, J.A.; Rose, N.R.; Čiháková, D. The varying faces of IL-6: From cardiac protection to cardiac failure. Cytokine 2015, 74, 62–68. [Google Scholar] [CrossRef] [PubMed]
- Ziegler, L.; Lundqvist, J.; Dreij, K.; Wallén, H.; de Faire, U.; Paulsson-Berne, G.; Hedin, U.; Matic, L.; Gigante, B. Expression of Interleukin 6 signaling receptors in carotid atherosclerosis. Vasc. Med. 2021, 26, 3–10. [Google Scholar] [CrossRef] [PubMed]
- Shahul, S.; Medvedofsky, D.; Wenger, J.B.; Nizamuddin, J.; Brown, S.M.; Bajracharya, S.; Salahuddin, S.; Thadhani, R.; Mueller, A.; Tung, A.; et al. Circulating Antiangiogenic Factors and Myocardial Dysfunction in Hypertensive Disorders of Pregnancy. Hypertension 2016, 67, 1273–1280. [Google Scholar] [CrossRef] [PubMed]
- Abou, R.; Bijl P van der Bax, J.J.; Delgado, V. Global longitudinal strain: Clinical use and prognostic implications in contemporary practice. Heart 2020, 106, 1438–1444. [Google Scholar] [CrossRef]
- Chiu, D.; Green, D.; Kalra, P.; Abidin, N. 128 Abnormal Global Longitudinal Strain is Associated with All-Cause Mortality in Haemodialysis Patients. Heart 2016, 102 (Suppl. S6), A90–A91. [Google Scholar] [CrossRef]
- Mosca, L.; Benjamin, E.J.; Berra, K.; Bezanson, J.L.; Dolor, R.J.; Lloyd-Jones, D.M.; Newby, L.K.; Piña, I.L.; Roger, V.L.; Shaw, L.J.; et al. Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 Update: A Guideline From the American Heart Association. J. Am. Coll. Cardiol. 2011, 57, 1404–1423. [Google Scholar] [CrossRef]
- Neuman, R.I.; Figaroa, A.M.J.; Nieboer, D.; Saleh, L.; Verdonk, K.; Danser, A.H.J.; Duvekot, H.J.J.; van den Meiracker, A.H.; van Lennep, J.R.; Visser, W. Angiogenic markers during preeclampsia: Are they associated with hypertension 1 year postpartum? Pregnancy Hypertens. 2021, 23, 116–122. [Google Scholar] [CrossRef]
- Gruson, D.; Hermans, M.P.; Ferracin, B.; Ahn, S.A.; Rousseau, M.F. Sflt-1 in heart failure: Relation with disease severity and biomarkers. Scand. J. Clin. Lab. Investig. 2016, 76, 411–416. [Google Scholar] [CrossRef]
- Mauricio, R.; Singh, K.; Sanghavi, M.; Ayers, C.R.; Rohatgi, A.; Vongpatanasin, W.; de Lemos, J.A.; Khera, A. Soluble Fms-like tyrosine kinase-1 (sFlt-1) is associated with subclinical and clinical atherosclerotic cardiovascular disease: The Dallas Heart Study. Atherosclerosis 2022, 346, 46–52. [Google Scholar] [CrossRef]
- Nakada, Y.; Kawakami, R.; Matsui, M.; Ueda, T.; Nakano, T.; Nakagawa, H.; Nishida, T.; Onoue, K.; Soeda, T.; Okayama, S.; et al. Value of Placental Growth Factor as a Predictor of Adverse Events During the Acute Phase of Acute Decompensated Heart Failure. Circ. J. 2019, 83, 395–400. [Google Scholar] [CrossRef]
- Systematic Review and Meta-Analysis: Anti–Tumor Necrosis Factor α Therapy and Cardiovascular Events in Rheumatoid Arthritis. Available online: https://onlinelibrary.wiley.com/doi/10.1002/acr.20371 (accessed on 3 July 2022).
- Fanola, C.L.; Morrow, D.A.; Cannon, C.P.; Jarolim, P.; Lukas, M.A.; Bode, C.; Hochman, J.S.; Goodrich, E.L.; Braunwald, E.; O’Donoghue, M.L. Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial. J. Am. Heart Assoc. 2017, 6, e005637. [Google Scholar] [CrossRef] [PubMed]
- Matsui, M.; Uemura, S.; Takeda, Y.; Samejima, K.I.; Matsumoto, T.; Hasegawa, A.; Tsushima, H.; Hoshino, E.; Ueda, T.; Morimoto, K.; et al. Placental Growth Factor as a Predictor of Cardiovascular Events in Patients with CKD from the NARA-CKD Study. J. Am. Soc. Nephrol. 2015, 26, 2871–2881. [Google Scholar] [CrossRef]
- Heeschen, C.; Dimmeler, S.; Fichtlscherer, S.; Hamm, C.W.; Berger, J.; Simoons, M.L.; Zeiher, A.M.; CAPTURE Investigators. Prognostic Value of Placental Growth Factor in Patients With Acute Chest Pain. JAMA 2004, 291, 435–441. [Google Scholar] [CrossRef] [PubMed]
- Vorovich, E.; French, B.; Ky, B.; Goldberg, L.; Fang, J.C.; Sweitzer, N.K.; Cappola, T.P. Biomarker predictors of cardiac hospitalization in chronic heart failure: A recurrent event analysis. J. Card. Fail. 2014, 20, 569–576. [Google Scholar] [CrossRef] [PubMed]
- Giorgione, V.; O’Driscoll, J.; Coutinho, C.M.; Di Fabrizio, C.; Sharma, R.; Khalil, A.; Thilaganathan, B. Peripartum echocardiographic changes in women with hypertensive disorders of pregnancy. Ultrasound Obstet. Gynecol. 2022, 59, 365–370. [Google Scholar] [CrossRef]
- deMartelly, V.A.; Dreixler, J.; Tung, A.; Mueller, A.; Heimberger, S.; Fazal, A.A.; Naseem, H.; Lang, R.; Kruse, E.; Yamat, M.; et al. Long-Term Postpartum Cardiac Function and Its Association With Preeclampsia. J. Am. Heart Assoc. 2021, 10, e018526. [Google Scholar] [CrossRef]
- Ghossein-Doha, C.; Peeters, L.; van Heijster, S.; van Kuijk, S.; Spaan, J.; Delhaas, T.; Spaanderman, M. Hypertension After Preeclampsia Is Preceded by Changes in Cardiac Structure and Function. Hypertension 2013, 62, 382–390. [Google Scholar] [CrossRef]
- Bernstein, H.; Sugimoto, J.; Suzuki-Kakisaka, H.; Romani, A. 823: Magnesium decreases inflammatory cytokine production: A novel innate immunomodulatory mechanism. Am. J. Obstet. Gynecol. 2012, 206, S361. [Google Scholar] [CrossRef]
- Xiao, J.; Yin, Y.; Shen, F.; Zhao, J.; Chen, Q. OS005. Treatment with magnesium sulphate reduced the serum level of IL-6in preeclamptic women. Pregnancy Hypertens. 2012, 2, 177. [Google Scholar] [CrossRef]
- Elango, T.; Dayalan, H.; Subramanian, S.; Gnanaraj, P.; Malligarjunan, H. Serum interleukin-6 levels in response to methotrexate treatment in psoriatic patients. Clin. Chim. Acta 2012, 413, 1652–1656. [Google Scholar] [CrossRef]
- Morton, A.C.; Rothman, A.M.K.; Greenwood, J.P.; Gunn, J.; Chase, A.; Clarke, B.; Hall, A.S.; Fox, K.; Foley, C.; Banya, W.; et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: The MRC-ILA Heart Study. Eur. Heart J. 2015, 36, 377–384. [Google Scholar] [CrossRef] [PubMed]
- Ridker, P.M.; Howard, C.P.; Walter, V.; Everett, B.; Libby, P.; Hensen, J.; Thuren, T.; CANTOS Pilot Investigative Group. Effects of Interleukin-1β Inhibition with Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen. Circulation 2012, 126, 2739–2748. [Google Scholar] [CrossRef] [PubMed]
- Ormesher, L.; Higson, S.; Luckie, M.; Roberts, S.A.; Glossop, H.; Trafford, A.; Cottrell, E.; Johnstone, E.D.; Myers, J.E. Postnatal Enalapril to Improve Cardiovascular Function Following Preterm Preeclampsia (PICk-UP). Hypertension 2020, 76, 1828–1837. [Google Scholar] [CrossRef] [PubMed]
TNF-α | IL-6 | IL-6/IL-10 | PlGF | sFlt-1 | sFlt-1/PlGF | |
---|---|---|---|---|---|---|
6 weeks | UC [13]: 89/5 UC [20]: 29/53 | UC [20]: 29/53 | UC [20] | |||
1–3 months | UC [21]: 43/50 | |||||
3 months | ↑ [22]: 17/16 UC [10]: 22/88 | ↑ [10,22] | ↑ [23]: 23/79 | UC [23] | UC [23] | |
9 months | UC [10] | ↑ [10] | ||||
1 year | ↑ [11]: 31/40 | UC [11] | UC [24]: 48/58 | ↑ [24] | ↑ [24] | |
5–8 years | UC [25]: 26/15 | ↑ [25] | ||||
9–16 years | UC [26]: 131/56 | ↑ [26] | ||||
10 years | UC [27]: 16/18 | UC [27] | ||||
11 years | UC [12]: 15/16 | UC [12] | ||||
12 years | UC [28]: 43/21 | UC [28] | UC [28] | |||
12–22 years | ↑ [29]: 249/2241 | |||||
20 years | UC [30] | ↑ [30] |
Intima Thickness | Intima: Media Thickness Ratio (I/M) | Intima–Media Thickness (cIMT) | |
---|---|---|---|
sFlt-1 | +0.38 [24]: 48 | +0.27 [28]: 43 | |
PlGF | −0.21 [24] | −0.21 [24] | −0.25 [28] |
sFlt-1/PlGF | +0.48 [24] | +0.41 [24] |
PlGF | sFlt-1 | |
---|---|---|
Left ventricle posterior wall thickness | +0.37 [28]: 43 | |
Global longitudinal strain | −0.58 [28] | +0.44 [21,43]: 43 |
End systolic elastance | +0.27 [21] | |
Arterial elastance | +0.24 [21] | |
E/E‘ | +0.096 [21] | |
E/A | −0.23 [21] | |
Aortic root diameter | − [14]: 3797 | |
Left atrial diameter | − [14] | |
Left ventricular mass | − [14] | +0.2 [43] |
Left ventricular ejection fraction | UC [43] |
PlGF | sFlt-1 | sFlt-1/PlGF | IL-6 | |
---|---|---|---|---|
Systolic blood pressure | [14]: 2924 | |||
Diastolic blood pressure | −0.29 [28]: 43 | |||
Mean arterial pressure | −0.25 [28] | + [43]: 62 | ||
Waist circumference | +0.26 [26]: 131 | |||
BMI | N [43] | +0.27 [26] | ||
Triglycerides | +0.155 [26] | |||
HDL | +0.34 [28] | −0.37 [28] | −0.31 [28] | −0.199 [26] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Maselienė, T.; Struckutė, E.; Breivienė, R.; Ramašauskaitė, D.; Dženkevičiūtė, V. The Importance of Inflammatory and Angiogenic Markers in the Evaluation of Early Cardiovascular Disease Risk in Women with Hypertensive Disorders of Pregnancy. J. Cardiovasc. Dev. Dis. 2023, 10, 407. https://doi.org/10.3390/jcdd10100407
Maselienė T, Struckutė E, Breivienė R, Ramašauskaitė D, Dženkevičiūtė V. The Importance of Inflammatory and Angiogenic Markers in the Evaluation of Early Cardiovascular Disease Risk in Women with Hypertensive Disorders of Pregnancy. Journal of Cardiovascular Development and Disease. 2023; 10(10):407. https://doi.org/10.3390/jcdd10100407
Chicago/Turabian StyleMaselienė, Tatjana, Emilija Struckutė, Rūta Breivienė, Diana Ramašauskaitė, and Vilma Dženkevičiūtė. 2023. "The Importance of Inflammatory and Angiogenic Markers in the Evaluation of Early Cardiovascular Disease Risk in Women with Hypertensive Disorders of Pregnancy" Journal of Cardiovascular Development and Disease 10, no. 10: 407. https://doi.org/10.3390/jcdd10100407